| Literature DB >> 27777794 |
Ruqayah G Y Al-Obaidi1, Bassam M S Al-Musawi2, Munib Ahmed K Al-Zubaidi3, Christian Oberkanins4, Stefan Németh4, Yusra G Y Al-Obaidi5.
Abstract
Congenital adrenal hyperplasia is a group of autosomal recessive disorders. The most frequent one is 21-hydroxylase deficiency. Analyzing CYP21A2 gene mutations was so far not reported in Iraq. This work aims to analyze the spectrum and frequency of CYP21A2 mutations among Iraqi CAH patients. Sixty-two children were recruited from the Pediatric Endocrine Consultation Clinic, Children Welfare Teaching Hospital, Baghdad, Iraq, from September 2014 till June 2015. Their ages ranged between one day and 15 years. They presented with salt wasting, simple virilization, or pseudoprecocious puberty. Cytogenetic study was performed for cases with ambiguous genitalia. Molecular analysis of CYP21A2 gene was done using the CAH StripAssay (ViennaLab Diagnostics) for detection of 11 point mutations and >50% of large gene deletions/conversions. Mutations were found in 42 (67.7%) patients; 31 (50%) patients were homozygotes, 9 (14.5%) were heterozygotes, and 2 (3.2%) were compound heterozygotes with 3 mutations, while 20 (32.3%) patients had none of the tested mutations. The most frequently detected mutations were large gene deletions/conversions found in 12 (19.4%) patients, followed by I2Splice and Q318X in 8 (12.9%) patients each, I172N in 5 (8.1%) patients, and V281L in 4 (6.5%) patients. Del 8 bp, P453S, and R483P were each found in one (1.6%) and complex alleles were found in 2 (3.2%). Four point mutations (P30L, Cluster E6, L307 frameshift, and R356W) were not identified in any patient. In conclusion, gene deletions/conversions and 7 point mutations were recorded in varying proportions, the former being the commonest, generally similar to what was reported in regional countries.Entities:
Year: 2016 PMID: 27777794 PMCID: PMC5061977 DOI: 10.1155/2016/9040616
Source DB: PubMed Journal: Enzyme Res ISSN: 2090-0414
Clinical presentation and age distribution of Iraqi CAH patients with 21-hydroxylase enzyme deficiency.
| Clinical presentation | Females | Males | Total | Age range |
|---|---|---|---|---|
| Classic | ||||
| Salt wasting form | 20 | 7 | 27 | 1 day–3 months |
| Simple virilizing form | 23 | 7 | 30 | 1 day–14 years |
| Nonclassic form | 4 | 1 | 5 | 8–15 years |
|
| ||||
| Total | 47 | 15 | 62 | 1 day–15 years |
Distribution of Iraqi CAH cases with 21-hydroxylase enzyme deficiency with large deletions/conversions of CYP21A2 gene.
| Types of deletions/conversions | Number (%) |
|---|---|
| P30L, I2Splice, Del 8 bp | 3 (4.8) |
| P30L, I2Splice, Del 8 bp, I172N | 2 (3.2) |
| Cluster E6, V281L, L307 frameshift, Q318X, R356W | 5 (8.1) |
| Complete | 2 (3.2) |
|
| |
|
|
|
Distribution of mutations in the tested alleles and zygosity status among Iraqi CAH cases.
| Homozygotes | Heterozygotes | Compound heterozygotes | Total detected | Undetected | Total | |
|---|---|---|---|---|---|---|
| Cases | 31 (50) | 9 (14.51) | 2 (3.23) | 42 (67.75) | 20 (32.25) |
|
| Tested alleles | 62 (50) | 18 (14.51) | 4 (32.23) | 75 (60.48) | 49 (39.52) |
|
| Mutations | 62 (50) | 9 (7.25) | 6 (4.83) | 77 (62.1)#
| 49 (39.52) |
|
Del = large deletion/conversion. PM = point mutation.
40 alleles from 20 homozygous cases plus 9 heterozygous cases where only one mutation was found.
Those two cases each carry 3 point mutations in their 2 alleles (I2Splice, Q318X, and Del 8 bp).
#77 mutations were detected in 75 alleles.
Ψ126 total number of mutations (77 were detected and 49 undetected) instead of 124 expected mutations.
Frequency of detected CYP21A2 mutations and zygosity status among Iraqi CAH patients.
| Type of mutation | Number of cases (number of alleles carrying that mutation) | Number (%) of mutant alleles | |
|---|---|---|---|
| Homozygous | Heterozygous | ||
| P30L | 0 | 0 |
|
| I2Splice | 8 (16) | 2 | 18 (14.5%) |
| Del 8 bp | 1 (2) | 2 | 4 (3.2%) |
| I172N | 5 (10) | 0 | 10 (8.1%) |
| Cluster E6 | 0 | 0 | 0 |
| V281l | 1 (2) | 3 (3) | 5 (4.03%) |
| L307 frameshift | 0 | 0 | 0 |
| Q318X | 4 (8) | 4 + 2 | 14 (11.3%) |
| R356W | 0 | 0 | 0 |
| P453S | 0 | 1 (1) | 1 (0.81%) |
| R483P | 0 | 1 (1) | 1 (0.81%) |
| Large deletions/conversions | 12 (24) | 0 | 24 (19.3%) |
|
| |||
|
|
|
| 77 mutations in 75 alleles (60.5%) |
|
| |||
|
|
| 49 (39.5%) | |
|
| |||
|
|
| ||
Two of these heterozygous cases were compound, each having 3 mutations (namely, I2Splice, Del 8 bp, and Q318X) in their 2 alleles.
#Additional 9 alleles were undetected in the 9 heterozygous cases; only one mutation was detected.
$Thirteen mutant alleles were detected in 11 patients (nine of them had a single detected mutation but the remaining two had 3 mutations as mentioned above).
Frequency of CYP21A2 mutations according to clinical presentation in 62 Iraqi CAH patients.
| Mutation type | Number of patients (%) | |||
|---|---|---|---|---|
| SW | SV | NC | Total | |
| Large deletions/conversions | 11 (40.7) | 1 (3.3) | 0 (0.0) | 12 (19.3) |
| Q318X | 4 (14.8) | 4 (13.3) | 0 (0.0) | 8 (12.9) |
| I2Splice | 5 (18.5) | 3 (10.0) | 0 (0.0) | 8 (12.9) |
| I172N | 0 (0.0) | 5 (16.7) | 0 (0.0) | 5 (8.1) |
| V281L | 0 (0.0) | 4 (13.3) | 0 (0.0) | 4 (6.4) |
| Del 8 bp | 1 (3.7) | 0 (0.0) | 0 (0.0) | 1 (1.6) |
| Multiple mutations | 1 (3.7) | 1 (3.3) | 0 (0.0) | 2 (3.2) |
| P453S | 0 (0.0) | 1 (3.3) | 0 (0.0) | 1 (1.6) |
| R483P | 0 (0.0) | 1 (3.3) | 0 (0.0) | 1 (1.6) |
|
| ||||
|
|
|
|
|
|
|
| ||||
| Not detected | 5 (18.5) | 10 (33.3) | 5 (100) | 20 (32.3) |
|
| ||||
|
|
|
|
|
|
Frequency of common allelic mutations in this study compared with previous studies from some of the neighboring and Arab countries.
| Present study, Iraq, 2015 | Turkey, 2009 [ | Jordan, 2011 [ | Iran, 2011 [ | Iran, 2008 [ | Tunisia, 2004 [ | |
|---|---|---|---|---|---|---|
| Total alleles ( | 124 | 91 | 92 | 88 | 100 | 102 |
| Not detected (%) | 39.5% | 15.4% | 40% | 0 | 30% | 5.9% |
| Molecular method(s) used | AS-PCR with reverse hybridization for 11 mutations | SB, AS-PCR/ER, and sequencing | ARMS for 8 common mutations & MLPA | AS-PCR for 8 common mutations and sequencing | AS-PCR for 8 mutations | ER + sequencing |
| P30L | 0 | 0 | 17.8 | 0 | 0 | 0 |
| I2Splice | 14.5 | 22.0 | 35.7 | 14.77 | 28 | 17.6 |
| Del 8 bp E3 | 3.2 | 4.4 | 16 | 0 | 13 | 0 |
| I172N | 8.1 | 9.9 | 16 | 5.68 | 9.0 | 10.8 |
| Cluster E6 | 0 | 2.2 | 1.7 | 2.27 | 4.0 | 0 |
| V281L | 4.0 | 7.6 | 0 | 1.14 | 3.0 | 0 |
| L307fs | 0 | 0 | NT | 0 | NT | 0 |
| Q318X | 11.3 | 3.3 | 23.2 | 15.91 | 9 | 35.3 |
| R356W | 0 | 8.8 | 3.5 | 7.95 | 5.0 | 2.0 |
| P453S | 0.81 | 2.2 | NT | NR | NT | NR |
| R483P | 0.81 | NR | NT | NR | NT | |
| Deletions/conversions | 19.3 | 8.8/14.3 | 0 | 31.8 | NT | 19.6 |
NR: not reported; NT: not tested; SB: southern blot; AS-PCR: allele-specific oligonucleotide hybridization by PCR; ER: enzyme restriction; ARMS: amplification refractory mutational screen; MLPA: multiplex ligation dependent probe amplification.